Evidence map›Paper›PMID 40290521›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

A GWAS of angiotensin-converting enzyme inhibitor-induced angioedema in a South African population.

Jacquiline W Mugo, Cascia Day, Ananyo Choudhury, Maria Deetlefs, Robert Freercks, Sian Geraty, Angelica Panieri, Christian Cotchobos, Melissa Ribeiro, Adelein Engelbrecht and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jacquiline W MugoDivision of Allergy and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Johannesburg, South Africa.
Cascia DayDivision of Allergy and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Johannesburg, South Africa.
Ananyo ChoudhurySydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Maria DeetlefsDivision of Allergy and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Johannesburg, South Africa.
Robert FreercksFaculty of Health Sciences, Department of Medicine, Nelson Mandela University, Gqeberhal, South Africa.
Sian GeratyFaculty of Health Sciences, Department of Medicine, Nelson Mandela University, Gqeberhal, South Africa.
Angelica PanieriFaculty of Health Sciences, Department of Medicine, Nelson Mandela University, Gqeberhal, South Africa.
Christian CotchobosFaculty of Health Sciences, Department of Medicine, Nelson Mandela University, Gqeberhal, South Africa.
Melissa RibeiroAllergy and Immunology Unit, University of Cape Town Lung Institute (Pty) Ltd, Johannesburg, South Africa.
Adelein EngelbrechtDistrict 6 Day Hospital, Cape Town, South Africa.
Lisa K MicklesfieldSouth African Medical Research Council/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Michèle RamsaySydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sarah PedrettiAllergy and Immunology Unit, University of Cape Town Lung Institute (Pty) Ltd, Johannesburg, South Africa.
Jonny PeterDivision of Allergy and Clinical Immunology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Johannesburg, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Angiotensin-converting enzyme inhibitor-induced angioedema (AE-ACEI) is a life-threatening adverse event; globally, it is the most common cause of emergency presentations with angioedema. Several genome-wide association studies (GWASs) have found genomic associations with AE-ACEI. However, despite African Americans having a 5-fold increased risk of AE-ACEI, there are no published GWASs from Africa. Objective: The aim of this study was to conduct a GWAS of AE-ACEI in a South African population and perform a meta-analysis with an African American and European American population. Methods: The GWAS included 202 South African adults with a history of AE-ACEI and 513 controls without angioedema following angiotensin-converting enzyme inhibitor (ACEI) treatment for at least 2 years. A meta-analysis was conducted with GWAS summary statistics from an African American and European American cohort (from the Vanderbilt-Marshfield cohort, which consisted of 174 case patients and 489 controls). Results: No single-nucleotide polymorphisms (SNPs) attained genome-wide significance; however, 26 SNPs in the postimputation standard GWAS of the South African cohort and 73 SNPs in the meta-analysis attained suggestive thresholds ( Conclusions: Our results highlight the importance of African populations for detection of novel variants in replication studies. Further increased sampling across the continent and matched functional work are needed to confirm the importance of genetic variation in understanding the biology of AE-ACEI.

Indexed as

Angioedemaangiotensin-converting enzyme inhibitorgenome-wide association studies

Identifiers

PMID40290521
PMCPMC12022653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.